Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
78.80    -1.00 (-1.25%)
Bid:
77.80
Ask:
78.30
Spread: 0.50 (0.643%)
Market Cap: £129.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading update

9 Nov 2016 07:00

RNS Number : 6789O
Synthomer PLC
09 November 2016
 

 

November 9th 2016

Synthomer plc

Q3 Trading update

Positive performance and Full Year 2016 guidance maintained

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the third quarter ('Q3') ended September 30th, 2016.

Trading

Europe and North America

Europe and North America has continued to trade well, in line with our expectations and consistent with the positive trends experienced through H1 2016. Q3 reported volumes were in line with last year whilst reported unit margins for the quarter were ahead of Q3 2015 and Q2 2016. Accordingly, with the exception of Paper latex, gross margins across all businesses were stronger than last year. This performance reflects the improved trading environment as well as the Group's focus on efficiency, new product initiatives, strengthened procurement function and investment in business development activities.

Asia and Rest of World

Asia and Rest of World has continued to trade in line with our expectations, with the competitive dynamics in our Asian Nitrile business evolving broadly as expected following the introduction of additional industry capacity.

Reported Asian volumes were marginally lower than last year but sequentially higher than Q2 2016, largely driven by increased volumes in the Asian Nitrile business. As expected, the market environment has led to overall unit margins softening from the highs seen in H2 2015 and H1 2016. Whilst the competitive dynamics in our Asian Nitrile business are continuing to evolve, this downward price pressure has not been as marked as the Group experienced in previous years. We continue to expect full year volumes and margins for this business to be similar to FY 2015.

Hexion PAC

The integration of Hexion PAC is well underway and progressing to plan. The underlying annual EBITDA and expected synergies remain unchanged from the guidance given to the market in March 2016.

Foreign currency

The Group has continued to benefit from the translation effect of the ongoing weakness of sterling. Average YTD FX rates are €1.24 and $1.38 which, if unchanged for the remainder of the year, would provide a translational benefit of approximately £10m for the full year.

Financial Position

The Group has generated strong cash flows in Q3, benefitting from Malaysian land sale and South African business sale receipts of £21m and £13m respectively. Net debt has reduced from £215m at 30 June to £159m at 30 September 2016.

The Group balance sheet remains strong with net debt/EBITDA ratio at circa 1.1x.

Outlook

The Board's expectations for Full Year 2016 remain unchanged from the interim results in August. Looking forward, the outlook in 2017 also remains consistent with our previous expectations underpinned by resilient trading in Europe despite a challenging macroeconomic environment, the Asian Nitrile market continuing to evolve broadly in line with our expectations and the ongoing integration of Hexion PAC.

 

Capital Markets Day

Synthomer plc will be hosting a Capital Markets Day for analysts and investors on Thursday December 1st. Senior members of Synthomer's management team will provide an update on strategy as well as present on the Group's two core divisions and R&D and innovation capabilities.

-ENDS-

ENQUIRIES:

Calum MacLean, Chief Executive Officer

Charles Armitstead

Stephen Bennett, Chief Financial Officer

Teneo Blue Rubicon

Tel: + 44 1279 436211

Tel: + 44 207 260 2700

 

 

The Company will hold a conference call for investors and analysts at 0800 GMT today. 

Please dial +44 (0) 808 2370030 entering conference ID: 31555005# to gain access to the call.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBPBLTMBTMBBF
Date   Source Headline
13th Aug 20124:32 pmRNSHolding(s) in Company
24th Jul 201210:23 amRNSHolding(s) in Company
20th Jul 20124:10 pmRNSHolding(s) in Company
16th Jul 20129:33 amRNSHolding(s) in Company
13th Jul 201210:38 amRNSChange of Auditor
6th Jul 20129:38 amRNSHolding(s) in Company
3rd Jul 20124:35 pmRNSHolding(s) in Company
2nd Jul 201212:46 pmRNSHolding(s) in Company
2nd Jul 201211:11 amRNSDirector/PDMR Shareholding
27th Jun 20127:00 amRNSTrading Statement
12th Jun 201210:30 amRNSDirector/PDMR Shareholding
8th Jun 20122:09 pmRNSDirector/PDMR Shareholding
7th Jun 20124:35 pmRNSDirector/PDMR Shareholding
25th May 201211:00 amRNSDirector Declaration
17th May 201212:22 pmRNSResult of AGM
17th May 201211:00 amRNSDirectorate Change
17th May 20127:00 amRNSInterim Management Statement
14th May 20123:47 pmRNSAnnual Information Update
17th Apr 20129:18 amRNSAnnual Financial Report
3rd Apr 20123:11 pmRNSDirector/PDMR Shareholding
2nd Apr 20127:00 amRNSMarl Site Operations
28th Mar 20125:15 pmRNSHolding(s) in Company
26th Mar 20127:00 amRNSDirector/PDMR Shareholding
23rd Mar 20127:00 amRNSDirectorate Change
19th Mar 20124:10 pmRNSDirector/PDMR Shareholding
16th Mar 20121:48 pmRNSDirector/PDMR Shareholding
16th Mar 20121:46 pmRNSDirector/PDMR Shareholding
16th Mar 20121:09 pmRNSDirector/PDMR Shareholding
14th Mar 20123:52 pmRNSDirector/PDMR Shareholding
14th Mar 20127:00 amRNSFinal Results
11th Jan 20127:00 amRNSTrading Update
9th Jan 201210:24 amRNSDirector/PDMR Shareholding
3rd Jan 20124:51 pmRNSDirector/PDMR Shareholding
1st Dec 20117:00 amRNSDisposal of Pharma Division
25th Nov 20117:00 amRNSDirectorate Change
10th Nov 20117:00 amRNSInterim Management Statement
1st Nov 20113:33 pmRNSHolding(s) in Company
31st Oct 201110:15 amRNSHolding(s) in Company
20th Oct 20112:42 pmRNSHolding(s) in Company
17th Oct 20118:20 amRNSAcquisition
28th Sep 20117:00 amRNSAnalyst and Investor Site Visit
5th Sep 20117:00 amRNSAppointment of Joint Broker
26th Aug 20117:00 amRNSHalf Yearly Report
10th Aug 20118:58 amRNSHolding(s) in Company
4th Aug 20119:02 amRNSBoard appointment
27th Jul 20111:12 pmRNSHolding(s) in Company
29th Jun 20114:46 pmRNSDirector/PDMR Shareholding
29th Jun 20114:44 pmRNSDirector/PDMR Shareholding
29th Jun 20112:17 pmRNSResult of EGM
22nd Jun 20113:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.